Dechra Pharmaceuticals PLC
DPHAY · OTC
6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | |
|---|---|---|---|---|
| Revenue | $761,500 | $681,800 | $608,000 | $515,100 |
| % Growth | 11.7% | 12.1% | 18% | – |
| Cost of Goods Sold | $335,200 | $297,000 | $262,100 | $223,500 |
| Gross Profit | $426,300 | $384,800 | $345,900 | $291,600 |
| % Margin | 56% | 56.4% | 56.9% | 56.6% |
| R&D Expenses | $60,800 | $36,100 | $32,400 | $28,400 |
| G&A Expenses | $359,200 | $178,600 | $151,300 | $134,900 |
| SG&A Expenses | $359,200 | $178,600 | $151,300 | $134,900 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $420,000 | $214,700 | $258,900 | $232,900 |
| Operating Income | $6,300 | $95,500 | $84,000 | $52,200 |
| % Margin | 0.8% | 14% | 13.8% | 10.1% |
| Other Income/Exp. Net | -$42,400 | -$18,200 | -$13,000 | -$17,800 |
| Pre-Tax Income | -$36,100 | $77,600 | $74,000 | $40,900 |
| Tax Expense | -$8,200 | $19,400 | $18,500 | $7,000 |
| Net Income | -$27,900 | $58,200 | $55,500 | $33,900 |
| % Margin | -3.7% | 8.5% | 9.1% | 6.6% |
| EPS | -0.24 | 0.54 | 0.51 | 0.33 |
| % Growth | -144.4% | 5.9% | 54.5% | – |
| EPS Diluted | -0.24 | 0.53 | 0.51 | 0.33 |
| Weighted Avg Shares Out | 113,477 | 108,333 | 108,120 | 103,133 |
| Weighted Avg Shares Out Dil | 114,095 | 108,987 | 108,751 | 103,482 |
| Supplemental Information | – | – | – | – |
| Interest Income | $800 | $100 | $8,800 | $100 |
| Interest Expense | $43,900 | $12,200 | $9,800 | $11,500 |
| Depreciation & Amortization | $89,700 | $89,100 | $15,500 | $14,200 |
| EBITDA | $86,700 | $178,900 | $162,000 | $131,000 |
| % Margin | 11.4% | 26.2% | 26.6% | 25.4% |